OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
April 13, 2022
Battles against antibiotic-resistant bacteria can be won with bacteriophages.
With high-concentration biologics, careful selection of excipients in formulation is crucial for reducing viscosity without destabilizing the protein.
March 02, 2022
Careful selection is essential for achieving viscosity reduction without protein destabilization.
January 01, 2022
New and emerging biotherapeutic molecules drive the need for innovative solutions to meet cold-chain requirements.
December 02, 2021
Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
October 22, 2021
Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.
EMA's CHMP has approved two new manufacturing sites and a ready-to-use formulation of Comirnaty.
October 02, 2021
The complexity of newer biotherapeutic molecules calls for alternative drug delivery strategies.
The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.
September 09, 2021
Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.